News on bioinformatics, software, genome analysis, variant classification, and IT in genetics, genomics, and molecular diagnostics.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
M2Gen has seen its research database grow substantially, but now the firm must make the data useful across its clinical, pharma, and MDx partners.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.
Ten sites across the US will seek to integrate genomic risk assessment into clinical care, with a focus on diverse populations.
